Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
Heat Shock Proteins and Human Cancers
share announcement

Heat Shock Proteins and Human Cancers

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1523

Special Issue Editor

Dr. Alexander E. Kabakov

E-Mail Website
Guest Editor
Department of Radiation Biochemistry, A. Tsyb Medical Radiological Research Center, Obninsk, Russia
Interests: heat shock proteins; molecular chaperones; cellular stress; protein folding; cancer; cancer stem cells; radiotherapy; hyperthermia; tumor radioresistance; radiosensitizers; anticancer drugs; DNA damage response; apoptosis; hypoxia in tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As the Guest Editor of the announced Special Issue, I am pleased to invite you to submit your manuscripts dedicated to Heat Shock Proteins and Cancer.   

The relationship between heat shock proteins (HSPs) and cancer has been actively studied in recent decades and many remarkable findings have been made in this field. HSPs were shown to promote tumorigenesis, aggressive tumor growth, and tumor resistance to therapeutics; therefore, many current studies focus on the development of HSP-based modalities for theranostics of cancers.

It is now known that HSPs are required for oncogene-mediated malignization and then protect malignant cells from apoptosis, senescence, and immune attack. It is also accepted that HSPs support the viability of tumor cells under stressful conditions in the microenvironment (such as hypoxia, nutrient deficiency, acidosis, and others). Moreover, HSPs contribute to the maintenance of cancer cell stemness and the epithelial-to-mesenchymal transition (which are associated with tumor progression, invasion, and metastases). Excess HSPs can preserve tumor cells from the cytotoxicity of therapeutic agents, including drugs and radiation exposure. Consequently, HSPs are considered to be potential targets for treating or sensitizing human malignancies. Moreover, certain HSPs may be used in cancer-related diagnostics/prognostics or as components of anticancer vaccines.       

This Special Issue primarily aims to present some recent advances in exploring HSPs that may be significant for cancer biology and cancer treatment. We welcome both research articles and reviews covering topics such as HSP-involving mechanisms of tumorigenesis, the role of HSPs in cancer pathogenesis, approaches to inhibitory targeting tumorous HSPs, approaches to HSP-based diagnostics of cancer, HSP-based anticancer vaccines, HSPs and cancer-related exosomes, HSP-containing nanoparticles that are used to fight cancer, etc. Glucose-regulated proteins (GRPs), as members of the HSP family, will also be the cancer-related subject of this Special Issue. 

I look forward to receiving your manuscripts.

Dr. Alexander Kabakov
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heat shock protein
  • glucose-regulated protein
  • cancer
  • tumorigenesis
  • theranostics
  • anticancer vaccine

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 7588 KiB  
Article
Development of a Humanized Antibody Targeting Extracellular HSP90α to Suppress Endothelial-Mesenchymal Transition-Enhanced Tumor Growth of Pancreatic Adenocarcinoma Cells
by Chi-Shuan Fan, Hui-Chen Hung, Chia-Chi Chen, Li-Li Chen, Yi-Yu Ke, Teng-Kuang Yeh, Chin-Ting Huang, Teng-Yuan Chang, Kuei-Jung Yen, Chung-Hsing Chen, Kee Voon Chua, John Tsu-An Hsu and Tze-Sing Huang
Cells 2024, 13(13), 1146; https://doi.org/10.3390/cells13131146 - 4 Jul 2024
Viewed by 599
Abstract
Extracellular HSP90α (eHSP90α) is a promoter of tumor development and malignant progression. Patients with malignancies, including pancreatic ductal adenocarcinoma (PDAC), have generally shown 5~10-fold increases in serum/plasma eHSP90α levels. In this study, we developed a humanized antibody HH01 to target eHSP90α and evaluated [...] Read more.
Extracellular HSP90α (eHSP90α) is a promoter of tumor development and malignant progression. Patients with malignancies, including pancreatic ductal adenocarcinoma (PDAC), have generally shown 5~10-fold increases in serum/plasma eHSP90α levels. In this study, we developed a humanized antibody HH01 to target eHSP90α and evaluated its anticancer efficacy. HH01, with novel complementarity-determining regions, exhibits high binding affinity toward HSP90α. It recognizes HSP90α epitope sites 235AEEKEDKEEE244 and 251ESEDKPEIED260, with critical amino acid residues E237, E239, D240, K241, E253, and K255. HH01 effectively suppressed eHSP90α-induced invasive and spheroid-forming activities of colorectal cancer and PDAC cell lines by blocking eHSP90α’s ligation with the cell-surface receptor CD91. In mouse models, HH01 potently inhibited the tumor growth of PDAC cell grafts/xenografts promoted by endothelial-mesenchymal transition-derived cancer-associated fibroblasts while also reducing serum eHSP90α levels, reflecting its anticancer efficacy. HH01 also modulated tumor immunity by reducing M2 macrophages and reinvigorating immune T-cells. Additionally, HH01 showed low aggregation propensity, high water solubility, and a half-life time of >18 days in mouse blood. It was not cytotoxic to retinal pigmented epithelial cells and showed no obvious toxicity in mouse organs. Our data suggest that targeting eHSP90α with HH01 antibody can be a promising novel strategy for PDAC therapy. Full article
(This article belongs to the Special Issue Heat Shock Proteins and Human Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

36 pages, 3587 KiB  
Review
Tumor Dormancy and Reactivation: The Role of Heat Shock Proteins
by Haneef Ahmed Amissah, Stephanie E. Combs and Maxim Shevtsov
Cells 2024, 13(13), 1087; https://doi.org/10.3390/cells13131087 - 23 Jun 2024
Viewed by 556
Abstract
Tumors are a heterogeneous group of cell masses originating in various organs or tissues. The cellular composition of the tumor cell mass interacts in an intricate manner, influenced by humoral, genetic, molecular, and tumor microenvironment cues that dictate tumor growth or suppression. As [...] Read more.
Tumors are a heterogeneous group of cell masses originating in various organs or tissues. The cellular composition of the tumor cell mass interacts in an intricate manner, influenced by humoral, genetic, molecular, and tumor microenvironment cues that dictate tumor growth or suppression. As a result, tumors undergo a period of a dormant state before their clinically discernible stage, which surpasses the clinical dormancy threshold. Moreover, as a genetically imprinted strategy, early-seeder cells, a distinct population of tumor cells, break off to dock nearby or extravasate into blood vessels to secondary tissues, where they form disseminated solitary dormant tumor cells with reversible capacity. Among the various mechanisms underlying the dormant tumor mass and dormant tumor cell formation, heat shock proteins (HSPs) might play one of the most important roles in how the dormancy program plays out. It is known that numerous aberrant cellular processes, such as malignant transformation, cancer cell stemness, tumor invasion, metastasis, angiogenesis, and signaling pathway maintenance, are influenced by the HSPs. An accumulating body of knowledge suggests that HSPs may be involved in the angiogenic switch, immune editing, and extracellular matrix (ECM) remodeling cascades, crucial genetically imprinted strategies important to the tumor dormancy initiation and dormancy maintenance program. In this review, we highlight the biological events that orchestrate the dormancy state and the body of work that has been conducted on the dynamics of HSPs in a tumor mass, as well as tumor cell dormancy and reactivation. Additionally, we propose a conceptual framework that could possibly underlie dormant tumor reactivation in metastatic relapse. Full article
(This article belongs to the Special Issue Heat Shock Proteins and Human Cancers)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop